National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 67775 [2023-21740]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 189 / Monday, October 2, 2023 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: September 27, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: September 26, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–21740 Filed 9–29–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
BILLING CODE 4140–01–P
Proposed Collection; 60-Day Comment
Request; ABCD Study® Audience
Feedback Teams (National Institute on
Drug Abuse)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
[FR Doc. 2023–21686 Filed 9–29–23; 8:45 am]
ACTION:
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Research and Development
of Vaccines and Monoclonal Antibodies for
Pandemic Preparedness (ReVAMPP) Centers
for Bunyavirales, Paramyxoviridae and
Picornoviridae (U19 Clinical Trial Not
Allowed).
Date: November 7–9, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Rockville, MD
20892 (Virtual Meeting).
Contact Person: Frank S. De Silva, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, MSC 9823, Rockville, MD
20892–9823, (240) 669–5023, fdesilva@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
VerDate Sep<11>2014
18:41 Sep 29, 2023
Jkt 262001
National Institutes of Health,
HHS.
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Notice.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection projects, the
National Institute on Drug Abuse
(NIDA) will publish periodic summaries
of proposed projects to be submitted to
the Office of Management and Budget
(OMB) for review and approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 60 days of the date of this
publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Dr. Kimberly LeBlanc Scientific
Program Manager, Division of
Extramural Research, National Institute
on Drug Abuse, C/O NIH Mail Center/
Dock 11, 3WFN Room 09C77 MSC 6021,
Gaithersburg, MD 20877 (20892 for
USPS), or call non-toll-free number
(301) 827–4102, or Email your request,
including your address, to:
kimberly.leblanc@nih.gov. Formal
requests for additional plans and
instruments must be requested in
writing.
SUPPLEMENTARY INFORMATION: Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: written
comments and/or suggestions from the
public and affected agencies are invited
to address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
SUMMARY:
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
67775
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimizes
the burden of the collection of
information on those who are to
respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Proposed Collection Title: Adolescent
Brain & Cognitive Development (ABCD)
StudySM—Audience Feedback Teams,
0925 –NEW, exp., date XX/XX/XXXX,
National Institute on Drug Abuse
(NIDA), National Institutes of Health
(NIH).
Need and Use of Information
Collection: The purpose of this
information collection request is to
solicit audience feedback to improve the
data collection process for the
Adolescent Brain Cognitive
Development (ABCD) Study. Started in
2015, the ABCD Study® follows a cohort
of over 10,000 young people from preadolescence into adulthood to
understand how growing brains are
shaped by experiences and biology. To
prepare for each year’s Study data
collection, the National Institute of
Health is collecting audience feedback
on a selection of survey questions and
research protocols. Parents/caregivers
and teens who are the same age as the
study cohort members but who are not
Study participants will review proposed
questions and give feedback on
questions’ clarity and acceptability.
Recommendations from these findings
help the ABCD Study team improve
their protocol for a more-successful data
collection.
Audience feedback activities will
include a mix of asynchronous and
scheduled, live data collection: webbased survey activities, virtual
discussion boards, individual
interviews, and discussions groups.
Assembling a cohort of audience
feedback participants who are familiar
with the ABCD Study and participate in
multiple data collection activities
minimizes the burden required to
familiarize new participants with the
purpose of the Study and the
expectations for audience feedback.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
172.
E:\FR\FM\02OCN1.SGM
02OCN1
]]>Agencies
[Federal Register Volume 88, Number 189 (Monday, October 2, 2023)]
[Notices]
[Page 67775]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-21740]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Research and Development of
Vaccines and Monoclonal Antibodies for Pandemic Preparedness
(ReVAMPP) Centers for Bunyavirales, Paramyxoviridae and
Picornoviridae (U19 Clinical Trial Not Allowed).
Date: November 7-9, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Rockville, MD
20892 (Virtual Meeting).
Contact Person: Frank S. De Silva, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, MSC 9823,
Rockville, MD 20892-9823, (240) 669-5023, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: September 26, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-21740 Filed 9-29-23; 8:45 am]
BILLING CODE 4140-01-P
